Uncategorized

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

Published

on

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version